NCT01297309 - A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 6, 2011

Primary Completion Date

June 8, 2018

Study Completion Date

June 8, 2018

Conditions

Hypoparathyroidism

Interventions

DRUG

NPSP558

All patients will inject NPSP558 individual titration of 25, 50, 75 or 100 μg SC QD into alternating thighs in the morning via a multidose injection pen device.

Trial Locations (14)

10032

Columbia University Medical Center, New York

10301

University Physicians Group, Staten Island

19104

Children's Hospital of Philadelphia, Philadelphia

27834

Physician East PA, Greenville

32224

Mayo Clinic Jacksonville, Jacksonville

45219

University of Cincinnati Bone Health and Osteoporosis Center, Cincinnati

46202

Indiana University School of Medicine, Indianapolis

48236

Michigan Bone & Mineral Clinic PC, Detroit

55905

Mayo Clinic Rochester, Rochester

60637

University of Chicago Medical Center, Chicago

78229

Cetero Research DGD Research Inc., San Antonio

90712

Advance Medical Research LLC, Lakewood

98664

The Vancouver Clinic, Vancouver

02114

Massachusetts General Hospital, Boston